B cell lymphoma
Conditions
Sponsors
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary participation in the clinical trials and sign the informed consent; 2. To be aged 18 to 70 years male and femal; 3. Patients with CD19+, CD22+ leukemia or lymphoma diagnosed by pathology and histology, meet the criteria of autologous hematopoietic stem cell transplantation, and patients are voluntary to accept through infusion of anti-CD19 CAR-T and anti-CD22 CAR-T cell therapy after HSCT; 4. Types of B cell malignancy: (1) B cell Acute lymphoblastic leukemia; (2) Indolent B cell lymphoma (CLL, FL, MZL, LPL, HCL); (3) Aggressive B cell lymphoma (DLBCL, BL, MCL); (4) Multiple myeloma; 5. Patients suitable to accept auto-HSCT, and meeting any of the following criteria: (1) Present residual disease or progressive disease after main therapy ; (2) Relapse after CR1; (3) Patients with high risk factors; (4) Failure to achieve remission or relapse after other cell immunotherapy ; (5) Eligible for allo-HSCT, but unable to implement; 6. Multiple organ function assessment: Creatinine =95%; Bilirubin 40%; 7. Without history of accepting anti-cancer therapy, including chemotherapy, radiotherapy, immunotherapy (immune suppressive drugs treatment) within 4 weeks of screening; 8. Adequate venous access for apheresis; 9. ECOG score =3 months.
Exclusion criteria
Exclusion criteria: 1. Pregnancy and nursing females; 2. Planning pregnancy within 1 year; 3. Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening; 4. Systemic fungal, bacterial, viral, or other infection that is not controlled, at the time of screening; 5. Active HBV/HCV infected; 6. Any human immunodeficiency virus (HIV) infection; 7. History of accepting systemic steroids treatments within 4 weeks; 8. Allergic to any cytokines or antibodies; 9. Participation in an investigational research study within 6 weeks before enrolled; 10. History of accepting systemic steroids treatments within 4 weeks; 11. History of mental disorders; 12. Drug abuse and addiction; 13. Other situations we think improper for the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Countries
China
Contacts
Public ContactZhou Jianfeng
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed